Brief: Sensei Biotherapeutics Presents Preclinical Data for SNS-101 at SITC 36th Annual Meeting
12/11/2021 12:31
Nov 12 (Reuters) - Sensei Biotherapeutics Inc SNSE.O :
* SENSEI BIOTHERAPEUTICS PRESENTS PRECLINICAL DATA FOR
SNS-101, A
PH-SELECTIVE ANTI-VISTA ANTIBODY, AT THE SOCIETY FOR
IMMUNOTHERAPY OF CANCER (SITC) 36TH ANNUAL MEETING
* SENSEI BIOTHERAPEUTICS INC - IND-ENABLING STUDIES UNDERWAY
FOR
SNS-101
Source text for Eikon: ID:nGNX6Z60Sv
Further company coverage: SNSE.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Faeth Therapeutics
See all newsU.S. STOCKS ON THE MOVE - Nvidia, Gold miners, Nike
U.S. STOCKS ON THE MOVE - Sunrun, JetBlue Airways, Dell Technologies
Faeth Therapeutics rises after FDA grants fast-track status for cancer drug
Brief: Faeth Therapeutics Announces FDA Grant Of Fast Track Designation For Piktor Plus Paclitaxel In Biomarker-Selected Advanced Endometrial Cancer
Brief: Faeth Therapeutics Strengthens Executive Team With Senior Leadership Appointments